Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Insights and challenges in tuberculosis vaccine development.

McShane H.

Lancet Respir Med. 2019 Sep;7(9):810-819. doi: 10.1016/S2213-2600(19)30274-7. Epub 2019 Aug 12. Review.

PMID:
31416767
2.

Nitric Oxide Modulates Metabolic Remodeling in Inflammatory Macrophages through TCA Cycle Regulation and Itaconate Accumulation.

Bailey JD, Diotallevi M, Nicol T, McNeill E, Shaw A, Chuaiphichai S, Hale A, Starr A, Nandi M, Stylianou E, McShane H, Davis S, Fischer R, Kessler BM, McCullagh J, Channon KM, Crabtree MJ.

Cell Rep. 2019 Jul 2;28(1):218-230.e7. doi: 10.1016/j.celrep.2019.06.018.

3.

The Humoral Immune Response to BCG Vaccination.

Tanner R, Villarreal-Ramos B, Vordermeier HM, McShane H.

Front Immunol. 2019 Jun 11;10:1317. doi: 10.3389/fimmu.2019.01317. eCollection 2019. Review.

4.

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

Manjaly Thomas ZR, Satti I, Marshall JL, Harris SA, Lopez Ramon R, Hamidi A, Minhinnick A, Riste M, Stockdale L, Lawrie AM, Vermaak S, Wilkie M, Bettinson H, McShane H.

PLoS Med. 2019 Apr 30;16(4):e1002790. doi: 10.1371/journal.pmed.1002790. eCollection 2019 Apr.

5.

Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.

Tanner R, O'Shea MK, White AD, Müller J, Harrington-Kandt R, Matsumiya M, Dennis MJ, Parizotto EA, Harris S, Stylianou E, Naranbhai V, Bettencourt P, Drakesmith H, Sharpe S, Fletcher HA, McShane H.

Sci Rep. 2019 Apr 3;9(1):5596. doi: 10.1038/s41598-019-41387-8.

6.

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells.

Tanner R, Smith SG, van Meijgaarden KE, Giannoni F, Wilkie M, Gabriele L, Palma C, Dockrell HM, Ottenhoff THM, McShane H.

J Immunol Methods. 2019 Jun;469:1-10. doi: 10.1016/j.jim.2019.01.006. Epub 2019 Jan 31.

7.

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.

Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM.

Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018.

8.

Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis Infection.

O'Shea MK, Fletcher TE, Muller J, Tanner R, Matsumiya M, Bailey JW, Jones J, Smith SG, Koh G, Horsnell WG, Beeching NJ, Dunbar J, Wilson D, Cunningham AF, McShane H.

Front Immunol. 2018 Dec 14;9:2893. doi: 10.3389/fimmu.2018.02893. eCollection 2018.

9.

Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin.

McNeill E, Stylianou E, Crabtree MJ, Harrington-Kandt R, Kolb AL, Diotallevi M, Hale AB, Bettencourt P, Tanner R, O'Shea MK, Matsumiya M, Lockstone H, Müller J, Fletcher HA, Greaves DR, McShane H, Channon KM.

Nat Commun. 2018 Dec 20;9(1):5409. doi: 10.1038/s41467-018-07714-9.

10.

Current approaches toward identifying a correlate of immune protection from tuberculosis.

Satti I, McShane H.

Expert Rev Vaccines. 2019 Jan;18(1):43-59. doi: 10.1080/14760584.2019.1552140. Epub 2018 Dec 3. Review.

PMID:
30466332
11.

Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1- CD4+ T cells.

Bull NC, Stylianou E, Kaveh DA, Pinpathomrat N, Pasricha J, Harrington-Kandt R, Garcia-Pelayo MC, Hogarth PJ, McShane H.

Mucosal Immunol. 2019 Mar;12(2):555-564. doi: 10.1038/s41385-018-0109-1. Epub 2018 Nov 16.

PMID:
30446726
12.

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection.

O'Shea MK, Tanner R, Müller J, Harris SA, Wright D, Stockdale L, Stylianou E, Satti I, Smith SG, Dunbar J, Fletcher TE, Dedicoat M, Cunningham AF, McShane H.

Sci Rep. 2018 Sep 27;8(1):14480. doi: 10.1038/s41598-018-32755-x.

13.

Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK.

Hayward S, Harding RM, McShane H, Tanner R.

Version 2. F1000Res. 2018 Apr 13 [revised 2018 Jan 1];7:461. doi: 10.12688/f1000research.14476.2. eCollection 2018. Review.

14.

Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies.

van Meijgaarden KE, Khatri B, Smith SG, Drittij AMFH, de Paus RA, Goeman JJ, Ho MM, Dockrell HM, McShane H, Joosten SA, Ottenhoff THM.

PLoS One. 2018 Sep 4;13(9):e0201205. doi: 10.1371/journal.pone.0201205. eCollection 2018.

15.

Induction and maintenance of a phenotypically heterogeneous lung tissue-resident CD4+ T cell population following BCG immunisation.

Bull NC, Kaveh DA, Garcia-Pelayo MC, Stylianou E, McShane H, Hogarth PJ.

Vaccine. 2018 Sep 5;36(37):5625-5635. doi: 10.1016/j.vaccine.2018.07.035. Epub 2018 Aug 7.

16.

WHO preferred product characteristics for new vaccines against tuberculosis.

Schrager LK, Chandrasekaran P, Fritzell BH, Hatherill M, Lambert PH, McShane H, Tornieporth N, Vekemans J.

Lancet Infect Dis. 2018 Aug;18(8):828-829. doi: 10.1016/S1473-3099(18)30421-3. No abstract available.

PMID:
30064668
17.

Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection.

Logan E, Luabeya AKK, Mulenga H, Mrdjen D, Ontong C, Cunningham AF, Tameris M, McShane H, Scriba TJ, Horsnell WGC, Hatherill M.

Front Immunol. 2018 Jul 2;9:1529. doi: 10.3389/fimmu.2018.01529. eCollection 2018.

18.

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.

Fletcher HA, Chatterjee M, Cooper A, Hussell T, Kaye PM, Prior J, Reljic R, Vermaak S, Vordermeier M, Williams A, McShane H.

F1000Res. 2018 Apr 23;7:485. doi: 10.12688/f1000research.14386.1. eCollection 2018.

19.

Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine.

Stylianou E, Harrington-Kandt R, Beglov J, Bull N, Pinpathomrat N, Swarbrick GM, Lewinsohn DA, Lewinsohn DM, McShane H.

Infect Immun. 2018 Jun 21;86(7). pii: e00014-18. doi: 10.1128/IAI.00014-18. Print 2018 Jul.

20.

Progress and challenges in TB vaccine development.

Voss G, Casimiro D, Neyrolles O, Williams A, Kaufmann SHE, McShane H, Hatherill M, Fletcher HA.

F1000Res. 2018 Feb 16;7:199. doi: 10.12688/f1000research.13588.1. eCollection 2018. Review.

21.

Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis-Specific T-Cell Responses.

Murray LW, Satti I, Meyerowitz J, Jones M, Willberg CB, Ussher JE, Goedhals D, Hurst J, Phillips RE, McShane H, Vuuren CV, Frater J.

J Infect Dis. 2018 May 5;217(11):1782-1792. doi: 10.1093/infdis/jiy052.

22.

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines.

Harris SA, White A, Stockdale L, Tanner R, Sibley L, Sarfas C, Meyer J, Peter J, O'Shea MK, Manjaly Thomas ZR, Hamidi A, Satti I, Dennis MJ, McShane H, Sharpe S.

Tuberculosis (Edinb). 2018 Jan;108:99-105. doi: 10.1016/j.tube.2017.11.006. Epub 2017 Nov 15.

23.

Helen McShane and colleagues reply to Deborah Cohen.

McShane H, Hill A, Hatherill M, Tameris M, Shea J, Ginsberg A.

BMJ. 2018 Jan 26;360:k236. doi: 10.1136/bmj.k236. No abstract available.

PMID:
29374008
24.

Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model.

Harrington-Kandt R, Stylianou E, Eddowes LA, Lim PJ, Stockdale L, Pinpathomrat N, Bull N, Pasricha J, Ulaszewska M, Beglov Y, Vaulont S, Drakesmith H, McShane H.

PLoS One. 2018 Jan 11;13(1):e0191038. doi: 10.1371/journal.pone.0191038. eCollection 2018.

25.

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals.

Schmidt BM, Tameris M, Geldenhuys H, Luabeya A, Bunyasi E, Hawkridge T, McClain JB, Mahomed H, Scriba TJ, McShane H, Hatherill M.

Trop Med Int Health. 2018 Jan;23(1):63-68. doi: 10.1111/tmi.13009. Epub 2017 Dec 4.

26.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; TBVAC2020 Consortium.

Front Immunol. 2017 Oct 4;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017. Review.

27.

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.

Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, Rose P, van der Zalm M, Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba TJ, McShane H, Hatherill M; MVA029 Study Team.

Clin Infect Dis. 2018 Feb 1;66(4):554-563. doi: 10.1093/cid/cix834.

28.

Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials.

Smith SG, Harris SA, Satti I, Bryan D, Walker KB, Dockrell HM, McShane H, Ho MM.

PLoS One. 2017 Oct 11;12(10):e0184391. doi: 10.1371/journal.pone.0184391. eCollection 2017.

29.

A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development.

Pepponi I, Khatri B, Tanner R, Villarreal-Ramos B, Vordermeier M, McShane H.

Tuberculosis (Edinb). 2017 Sep;106:118-122. doi: 10.1016/j.tube.2017.07.008. Epub 2017 Jul 22.

30.

The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014.

Brennan MJ, Tanner R, Morris S, Scriba TJ, Achkar JM, Zelmer A, Hokey DA, Izzo A, Sharpe S, Williams A, Penn-Nicholson A, Erasmus M, Stylianou E, Hoft DF, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00142-17. doi: 10.1128/CVI.00142-17. Print 2017 Sep. Review.

31.

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.

Bunyasi EW, Luabeya AKK, Tameris M, Geldenhuys H, Mulenga H, Landry BS, Scriba TJ, Schmidt BM, Hanekom WA, Mahomed H, McShane H, Hatherill M.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):778-783. doi: 10.5588/ijtld.16.0709.

32.

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.

Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H.

PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May.

33.

The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.

Tanner R, O'Shea MK, White AD, Müller J, Harrington-Kandt R, Matsumiya M, Dennis MJ, Parizotto EA, Harris S, Stylianou E, Naranbhai V, Bettencourt P, Drakesmith H, Sharpe S, Fletcher HA, McShane H.

Sci Rep. 2017 Mar 3;7:43478. doi: 10.1038/srep43478. Erratum in: Sci Rep. 2019 Apr 3;9(1):5596.

34.

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M.

Lancet Respir Med. 2017 Apr;5(4):282-290. doi: 10.1016/S2213-2600(17)30060-7. Epub 2017 Feb 16.

35.

Extracting Metallic Nanoparticles from Soils for Quantitative Analysis: Method Development Using Engineered Silver Nanoparticles and SP-ICP-MS.

Schwertfeger DM, Velicogna JR, Jesmer AH, Saatcioglu S, McShane H, Scroggins RP, Princz JI.

Anal Chem. 2017 Feb 21;89(4):2505-2513. doi: 10.1021/acs.analchem.6b04668. Epub 2017 Jan 30.

PMID:
28192905
36.

Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology.

Heinson AI, Gunawardana Y, Moesker B, Hume CC, Vataga E, Hall Y, Stylianou E, McShane H, Williams A, Niranjan M, Woelk CH.

Int J Mol Sci. 2017 Feb 1;18(2). pii: E312. doi: 10.3390/ijms18020312.

37.

Clinical Testing of Tuberculosis Vaccine Candidates.

Hatherill M, Tait D, McShane H.

Microbiol Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.TBTB2-0015-2016. Review.

PMID:
28087924
38.

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods.

Rhodes SJ, Sarfas C, Knight GM, White A, Pathan AA, McShane H, Evans TG, Fletcher H, Sharpe S, White RG.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00525-16. doi: 10.1128/CVI.00525-16. Print 2017 Mar.

39.

Antibodies and tuberculosis.

Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ.

Tuberculosis (Edinb). 2016 Dec;101:102-113. doi: 10.1016/j.tube.2016.08.001. Epub 2016 Aug 26. Review.

40.

Replacing, reducing and refining the use of animals in tuberculosis vaccine research.

Tanner R, McShane H.

ALTEX. 2017;34(1):157-166. doi: 10.14573/altex.1607281. Epub 2016 Sep 26.

41.

In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy.

Tanner R, O'Shea MK, Fletcher HA, McShane H.

Vaccine. 2016 Sep 7;34(39):4656-4665. doi: 10.1016/j.vaccine.2016.07.058. Epub 2016 Aug 12. Review.

42.

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.

Zelmer A, Tanner R, Stylianou E, Damelang T, Morris S, Izzo A, Williams A, Sharpe S, Pepponi I, Walker B, Hokey DA, McShane H, Brennan M, Fletcher H.

BMC Infect Dis. 2016 Aug 12;16:412. doi: 10.1186/s12879-016-1751-4.

43.

In field conditions, commercial pigment grade TiO2 was not harmful to terrestrial isopods but reduced leaf litter fragmentation.

Jemec A, Kos M, Drobne D, Koponen IK, Vukić J, Ferreira NG, Loureiro S, McShane HV.

Sci Total Environ. 2016 Nov 15;571:1128-35. doi: 10.1016/j.scitotenv.2016.07.107.

PMID:
27481455
44.

TB vaccines in clinical development.

Ginsberg AM, Ruhwald M, Mearns H, McShane H.

Tuberculosis (Edinb). 2016 Aug;99 Suppl 1:S16-20. doi: 10.1016/j.tube.2016.05.013. Epub 2016 Jun 16.

PMID:
27470538
45.

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review.

McShane H, Hatherill M, Hanekom W, Evans T.

Int J Epidemiol. 2016 Apr;45(2):580. doi: 10.1093/ije/dyw058. No abstract available.

46.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 May 6;7:11633. doi: 10.1038/ncomms11633. No abstract available.

47.

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.

48.

Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction.

Chen T, Blanc C, Eder AZ, Prados-Rosales R, Souza AC, Kim RS, Glatman-Freedman A, Joe M, Bai Y, Lowary TL, Tanner R, Brennan MJ, Fletcher HA, McShane H, Casadevall A, Achkar JM.

J Infect Dis. 2016 Jul 15;214(2):300-10. doi: 10.1093/infdis/jiw141. Epub 2016 Apr 7.

49.

Why don't we have an effective tuberculosis vaccine yet?

Davenne T, McShane H.

Expert Rev Vaccines. 2016 Aug;15(8):1009-13. doi: 10.1586/14760584.2016.1170599. Epub 2016 May 3. Review.

50.

Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes.

Naranbhai V, Fletcher HA, Tanner R, O'Shea MK, McShane H, Fairfax BP, Knight JC, Hill AV.

EBioMedicine. 2015 Nov;2(11):1619-26.

Supplemental Content

Loading ...
Support Center